Skip to main content
. Author manuscript; available in PMC: 2015 Apr 23.
Published in final edited form as: Nat Commun. 2015 Jan 5;6:5845. doi: 10.1038/ncomms6845

Figure 6. TDP-43 acetylation is a pathological feature of ALS but not FTLD-TDP.

Figure 6

a-f) Immunohistochemistry (IHC) was performed on cortical brain and spinal cord sections from frontotemporal dementia (FTLD-TDP) and ALS cases that harbor abundant TDP-43 pathology. Shown are representative images of TDP-43 inclusions detected with phosphorylated (P-409/410) and acetylated (Ac-K145) TDP-43 antibodies. FTLD-TDP inclusions showed characteristic phosphorylated TDP-43 immunoreactivity with P-409/410 (a), which was not detected with Ac-K145 (b). Serial ALS spinal cord sections analyzed by IHC identified TDP-43 inclusions that were immunoreactive with both P409/410 (c, e) and Ac-K145 antibodies (d, f), indicating acetylation of TDP-43 in ALS spinal cord lesions. See Table 1 for a summary of P-409/410 and Ac-K145 immunoreactivity and details of ALS cases used in this study. g-i) Double labeling immunofluorescence was performed on ALS spinal cord sections using monoclonal anti-TDP-43 (panel g, red) and Ac-K145 (panel h, green) antibodies. The merged image (panel i) highlights the co-localization observed between total TDP-43 and acetylated TDP-43. Scale bar represents 50 µm (panels a-d) and 10 µm (panels e-f and g-i).

HHS Vulnerability Disclosure